JPRN-jRCTs041200012进行中（未招募）2 期
Phase 2 study of Pembrolizumab plus pemetrexed for elderly patients with non-squamous non-small cell lung cancer with PD-L1 tumor proportion score of less than 50%: CJLSG1901 - NMC-CJLSG1901
Kogure Yoshihito0 个研究点目标入组 49 人开始时间: 2020年5月25日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 49
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 75age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1)Non-squamous non-small cell lung cancer (NSCLC) confirmed by histology or cytology.
- •2)Not received prior systemic treatment with stage IV, or recurrent NSCLC.
- •Subjects who received adjuvant therapy are eligible if the adjuvant therapy was completed at least 12 months prior to the development of metastatic disease.
- •3)PD-L1 TPS of less than 50% with 22C3 antibody.
- •4)With at least one measurable lesion based on RECIST 1.1.
- •5)Age of 75 years or older on the day of informed consent.
- •6)ECOG Performance Status 0-1.
- •7)Without activating mutation in EGFR or ALK chromosomal translocation.
- •8)Absence of severe impairments of major organs.
- •9)Life expectancy of 12 weeks or more from the treatment start date.
- •10)Prior to the study registration, able to provide written informed consent after a thorough explanation of the study content.
排除标准
- •1)Before the first dose of trial treatment:
- •Had major surgery (<3 weeks prior to the first dose)
- •2)Received radiation therapy to the lung that exceeds 30 Gy within 6 months of the first dose of the study treatment.
- •3)Completed palliative radiotherapy within 7 days of the first dose of the treatment.
- •4)Has received a live-virus vaccination within 30 days of planned treatment initiation.
- •Seasonal flu vaccines that do not contain live virus are permitted.
- •5)Has clinically active diverticulitis, intra-abdominal abscess, GI obstruction, peritoneal carcinomatosis.
- •6)Has a history of malignancy except if the subject has undergone curative therapy without recurrence for 5 years since initiation of that therapy.
- •7)Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
- •8)Previously had a severe hypersensitivity reaction to treatment with another mAb.
- •9)Has a known sensitivity to any component of pemetrexed
- •10)Has active autoimmune disease that has required systemic treatment in past 2 years
- •11)Is on chronic systemic steroids. Subjects with asthma that require intermittent use of bronchodilators, inhaled steroids, or local steroid injections would not be excluded from the study.
- •12)Is unable to interrupt aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs), other than an aspirin.
- •13)Is unable or unwilling to take folic acid or vitamin B12 supplementation.
- •14)Had prior treatment with any other anti-PD-1, or PD-L1 or PD-L2 agent or an antibody targeting other immuno-regulatory receptors or mechanisms.
- •15)Has an active infection requiring therapy.
- •16)Has a history of Human Immunodeficiency Virus (HIV)
- •17)Has known active Hepatitis B or C. Active Hepatitis B is defined as a known positive HBsAg result.
- •18)Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the Principal Investigator.
- •19)Has symptomatic ascites or pleural effusion.
- •20)Has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis.
- •21)Is expecting to conceive or father children within the projected duration of the study.
研究者
相似试验
进行中（未招募）
1 期
Phase II trial of Pembrolizumab in combination with Doxorubicin in Advanced, Recurrent or Metastatic Endometrial Cancer (TOPIC)Advanced, Recurrent or Metastatic Endometrial CancerMedDRA version: 12.0 Level: HLGT Classification code 10007129 Term: Cancer-related morbidities System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-002824-26-ESVall d' Hebron Institute of Oncology (VHIO)51
进行中（未招募）
2 期
A phase 2 study of pembrolizumab in combination with olaparib in patients with cervical cancer previously treated with platinum-based chemotherapyrecurrent or metastatic cervical cancercervical cancer ,Pembrolizumab,OlaparibJPRN-jRCT2031210096Hasegawa Kosei28
招募中
不适用
Phase II trial of pembrolizumab in combination with paclitaxel in the hormone receptor-positive metastatic breast cancer with high tumor mutational burden selected by whole exome sequencing: Korean Cancer Study Group trialKCT0007042Yonsei University Health System, Severance Hospital52
招募中
1 期
A Phase 2 clinical trial of Pembrolizumab in combination with Carboplatin and Cabazitaxel in Aggressive Variant Metastatic Castration Resistant Prostate CancerCTIS2022-501139-17-01Fundación Oncosur42
进行中（未招募）
1 期
PROMO: A phase II study of Pembrolizumab in patients with Relapsed Or Metastatic Osteosarcoma not eligible for curative surgeryEUCTR2016-001676-29-ITOSLO UNIVERSITETSSYKEHUS HF25